| Name | Title | Contact Details |
|---|
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.
eMobileApps is a Flowery Branch, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VentureMed Group, Inc. is a commercial-stage medical device company that develops and markets cost-effective interventional devices to improve the treatment of peripheral artery disease.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.
We are passionate about our work and compassionate toward our people, whether they work here or seek care from us. We opened the first AbsoluteCare center in Atlanta in 2000, with a primary focus on treating members with HIV/AIDS. We quickly became an HIV Center of Excellence, achieving impressive results: an 88 percent retention rate and a 97 percent undetectable rate. A surprising thing happened. With so many of them free of the symptoms of HIV/AIDS, our members sought primary care from us. They were coming in for help controlling asthma, diabetes, heart disease, hypertension, and all the other conditions that life and aging had thrown their way. So we transformed. We assembled a larger team of qualified, passionate practitioners to offer whole-life care in a new, larger center. And in the last two decades, we have expanded our facilities to multiple locations in several states, where we offer our members everything from primary care to nutrition counseling, behavioral health, and life services. The members who set foot in an AbsoluteCare center are usually underserved. With their health already compromised, life`s daily stressors add to their level of need.